Kinnate Biopharma Inc. (KNTE)
NASDAQ: KNTE
· Real-Time Price · USD
2.65
-0.01 (-0.38%)
At close: Apr 02, 2024, 8:00 PM
-0.38% (1D)
| Bid | n/a |
| Market Cap | 124.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -110.94M |
| EPS (ttm) | -2.78 |
| PE Ratio (ttm) | -0.9532374100719424 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 2,121,570 |
| Avg. Volume (20D) | 367,164 |
| Open | 2.65 |
| Previous Close | 2.66 |
| Day's Range | 2.64 - 2.67 |
| 52-Week Range | 1.04 - 7.18 |
| Beta | 1.34 |
About KNTE
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growt...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 3, 2020
Employees 84
Stock Exchange NASDAQ
Ticker Symbol KNTE
Website https://www.kinnate.com